Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer

Abstract

There remains an unmet need for targeted therapies against advanced non-small-cell lung cancer (NSCLC) with HER2 mutations. To improve the antitumor activity of single anti-HER2 agent, this prospective, single-arm clinical trial (NCT05016544) examined the safety profile and efficacy of anti-HER2 antibody inetetamab and pan-HER TKI pyrotinib in HER2-posivite advanced NSCLC patients. Enrolled patients received inetetamab every 3 weeks and pyrotinib once per day (pyrotinib, dose-escalation part, 240 mg, 320 mg; dose-expansion part, 320 mg). Primary endpoints were dose-limiting toxicity (DLT) dosage and safety. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). A total of 48 patients were enrolled. During the dose-escalation period, no DLT occurred. Diarrhea was the most commonly reported treatment-related adverse event (TRAE). Grade 3 TRAEs occurred in seven patients. The median PFS (mPFS) was 5.5 months [95% confidence interval (CI): 4.4–8.6 months]. The confirmed ORR and DCR reached 25% (11/44) and 84.1% (37/44), respectively. Responses were shown in patients with distinct HER2 aberrations. In summary, inetetamab in combination with pyrotinib demonstrated acceptable safety and antitumor activity among patients with advanced HER2-mutant NSCLC.

Keywords

HER2 mutations / inetetamab / non-small cell lung cancer / pyrotinib

References

1	RL Siegel, AN Giaquinto, A Jemal. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:
2	AC Tan, DSW Tan. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611-625. doi:
3	SR Yang, AM Schultheis, H Yu, D Mandelker, M Ladanyi, R Buttner. Precision medicine in non-small cell lung cancer: current applications and future directions. Semin Cancer Biol. 2022;84: 184-198. doi:
4	H Shigematsu, T Takahashi, M Nomura, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65(5):1642-1646. doi:
5	ME Arcila, JE Chaft, K Nafa, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18(18):4910-4918. doi:
6	J Mazieres, S Peters, B Lepage, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997-2003. doi:
7	J Mazieres, F Barlesi, T Filleron, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 2016;27(2):281-286. doi:
8	MG Kris, DR Camidge, G Giaccone, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015;26(7):1421-1427. doi:
9	R Dziadziuszko, EF Smit, U Dafni, et al. Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol. 2019;14(6):1086-1094. doi:
10	Y Yu, Y Yang, H Li, Y Fan. Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges. Cancer Treat Rev. 2023;114:102520. doi:
11	YY Elamin, JP Robichaux, BW Carter, et al. Poziotinib for patients with HER2 exon 20 mutant non-small-cell lung cancer: results from a phase II trial. J Clin Oncol. 2022;40(7):702-709. doi:
12	X Le, R Cornelissen, M Garassino, et al. Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial. J Clin Oncol. 2022;40(7):710-718. doi:
13	C Zhou, X Li, Q Wang, et al. Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II study. J Clin Oncol. 2020;38(24):2753-2761. doi:
14	Z Song, Y Li, S Chen, et al. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. BMC Med. 2022;20(1):42. doi:
15	BT Li, R Shen, D Buonocore, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36(24):2532-2537. doi:
16	BT Li, EF Smit, Y Goto, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386(3):241-251. doi:
17	Z Shao, D Pang, H Yang, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol. 2020;6(3):e193692. doi:
18	J Wu, Z Jiang, Z Liu, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 2022;20(1):498. doi:
19	J Cui, Y He, F Zhu, et al. Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma. Int J Biol Sci. 2023;19(13):4061-4081. doi:
20	T Wang, P Zhang, L Di, et al. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study. Transl Breast Cancer Res. 2022;3: 15. doi:
21	L Bian, BH Xu, LJ Di, et al. [Phase III randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES study]. Zhonghua Yi Xue Za Zhi. 2020;100(30):2351-2357. doi:
22	L Deng, L Zhao, L Liu, H Huang. Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers. Open Life Sci. 2023;18(1):20220535. doi:
23	N Jin, Y Xu, S Wang, et al. Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: a single-arm phase 2 clinical trial. Cancer Pathog Ther. 2024;2(1):31-37. doi:
24	J Zhao, Y Cai, L Ding, et al. Abstract OT3-25-02: inetetamab combined with pyrotinib and chemotherapy in pretreated patients with HER2-positive metastatic breast cancer, a single arm, multicenter phase II clinical trial. Cancer Res. 2023;83(5):OT3-25-02. doi:
25	JD Hainsworth, F Meric-Bernstam, C Swanton, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536-542. doi:
26	JM van Berge Henegouwen, M Jebbink, LR Hoes, et al. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. Eur J Cancer. 2022;171: 114-123. doi:
27	X Zhang, J Chen, Z Weng, et al. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action. Mol Immunol. 2020;119: 48-58. doi:
28	LC Tsao, J Force, ZC Hartman. Mechanisms of therapeutic antitumor monoclonal antibodies. Cancer Res. 2021;81(18):4641-4651. doi:
29	HY Chew, PO De Lima, JL Gonzalez Cruz, et al. Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies. Cell. 2020;180(5):895-914.e27. doi:
30	S Zhao, W Zhuang, B Han, et al. Phase 1b trial of anti-EGFR antibody JMT101 and osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. Nat Commun. 2023;14(1):3468. doi:
31	S Zhao, W Fang, H Pan, et al. Conformational landscapes of HER2 exon 20 insertions explain their sensitivity to kinase inhibitors in lung adenocarcinoma. J Thorac Oncol. 2020;15(6):962-972. doi:
32	H Hasegawa, H Yasuda, J Hamamoto, et al. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. Lung Cancer. 2019;127: 146-152. doi:
33	B van Veggel, AJ de Langen, SMS Hashemi, et al. Afatinib and cetuximab in four patients with EGFR exon 20 insertion-positive advanced NSCLC. J Thorac Oncol. 2018;13(8):1222-1226. doi:
34	F Ma, Q Li, S Chen, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35(27):3105-3112. doi: